SLN
Silence Therapeutics plc
Key Financials
Operating Income
$-91077000
↓ 43.8%
Revenue
$559000
↓ 98.7%
Gross Profit
$344000
↓ 98.9%
Net Income
$-88612000
↓ 95.6%
EPS (Diluted)
$-0.63
↓ 90.9%
Total Assets
$131.4M
↓ 35.1%
Total Liabilities
$69.1M
↑ 0.8%
Cash & Equivalents
$11.3M
↓ 90.7%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| SCHEDULE 13D/A | 8/13/2026 | View on SEC |
| SCHEDULE 13G/A | 8/13/2026 | View on SEC |
| 4 | 8/13/2026 | View on SEC |
| 8-K | 8/12/2026 | View on SEC |
| 424B5 | 8/12/2026 | View on SEC |
| S-3MEF | 8/11/2026 | View on SEC |
| 424B5 | 8/10/2026 | View on SEC |
| 8-K | 8/10/2026 | View on SEC |
| 10-Q | 8/10/2026 | View on SEC |
| 8-K | 8/10/2026 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | SLN |
| Company Name | Silence Therapeutics plc |
| CIK | 1479615 |
| Sector | Pharmaceutical Preparations |
| Industry | Non-accelerated filer Smaller reporting company |
| Exchange | Nasdaq |
| SIC Code | 2834 |
| SIC Description | Pharmaceutical Preparations |
| Entity Type | operating |
| State of Incorporation | X0 |
| Phone | 44-0-20-3457 6900 |